[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Global Drugs of UDCA and t-UDCA Market Research Report 2023

December 2023 | 93 pages | ID: GDC2468FEFE8EN
QYResearch

US$ 2,900.00

E-mail Delivery (PDF)

Download PDF Leaflet

Accepted cards
Wire Transfer
Checkout Later
Need Help? Ask a Question
Ursodeoxycholic Acid is an important clinical drug in the treatment of gallstones, cholecystitis, PBC, and PSC and has broad market prospects. In previous work, ursodeoxycholic acid was prepared by traditional organic synthesis.

According to QYResearch’s new survey, global Drugs of UDCA and t-UDCA market is projected to reach US$ 3948.8 million in 2029, increasing from US$ 1713.8 million in 2022, with the CAGR of 12.8% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Drugs of UDCA and t-UDCA market research.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Report Scope

This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Drugs of UDCA and t-UDCA market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.

By Company
  • Dr. Falk Pharma
  • Daewoong Pharmaceutical
  • Teva
  • Epic Pharma
  • Mitsubishi Tanabe Pharma
  • Lannett
  • Viatris
  • Bruschettini
  • Impax
  • Shanghai Pharma
  • Grindeks
Segment by Type
  • t-UDCA
  • UDCA
Segment by Application
  • Gallstone
  • Hepatopathy
  • Biliary Disease
  • Other
Consumption by Region
  • North America
    • United States
    • Canada
  • Europe
    • Germany
    • France
    • U.K.
    • Italy
    • Russia
  • Asia-Pacific
    • China
    • Japan
    • South Korea
    • India
    • Australia
    • China Taiwan
    • Indonesia
    • Thailand
    • Malaysia
  • Latin America
    • Mexico
    • Brazil
    • Argentina
  • Middle East & Africa
    • Turkey
    • Saudi Arabia
    • UAE
The Drugs of UDCA and t-UDCA report covers below items:

Chapter 1: Product Basic Information (Definition, Type and Application)

Chapter 2: Manufacturers’ Competition Patterns

Chapter 3: Country Level Sales Analysis

Chapter 4: Product Type Analysis

Chapter 5: Product Application Analysis

Chapter 6: Manufacturers’ Outline

Chapter 7: Industry Chain, Market Channel and Customer Analysis

Chapter 8: Market Opportunities and Challenges

Chapter 9: Market Conclusions

Chapter 10: Research Methodology and Data Source
1 DRUGS OF UDCA AND T-UDCA MARKET OVERVIEW

1.1 Product Overview and Scope of Drugs of UDCA and t-UDCA
1.2 Drugs of UDCA and t-UDCA Segment by Type
  1.2.1 Global Drugs of UDCA and t-UDCA Market Value Comparison by Type (2023-2029)
  1.2.2 t-UDCA
  1.2.3 UDCA
1.3 Drugs of UDCA and t-UDCA Segment by Application
  1.3.1 Global Drugs of UDCA and t-UDCA Market Value by Application: (2023-2029)
  1.3.2 Gallstone
  1.3.3 Hepatopathy
  1.3.4 Biliary Disease
  1.3.5 Other
1.4 Global Drugs of UDCA and t-UDCA Market Size Estimates and Forecasts
  1.4.1 Global Drugs of UDCA and t-UDCA Revenue 2018-2029
  1.4.2 Global Drugs of UDCA and t-UDCA Sales 2018-2029
  1.4.3 Global Drugs of UDCA and t-UDCA Market Average Price (2018-2029)
1.5 Assumptions and Limitations

2 DRUGS OF UDCA AND T-UDCA MARKET COMPETITION BY MANUFACTURERS

2.1 Global Drugs of UDCA and t-UDCA Sales Market Share by Manufacturers (2018-2023)
2.2 Global Drugs of UDCA and t-UDCA Revenue Market Share by Manufacturers (2018-2023)
2.3 Global Drugs of UDCA and t-UDCA Average Price by Manufacturers (2018-2023)
2.4 Global Drugs of UDCA and t-UDCA Industry Ranking 2021 VS 2022 VS 2023
2.5 Global Key Manufacturers of Drugs of UDCA and t-UDCA, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Drugs of UDCA and t-UDCA, Product Type & Application
2.7 Drugs of UDCA and t-UDCA Market Competitive Situation and Trends
  2.7.1 Drugs of UDCA and t-UDCA Market Concentration Rate
  2.7.2 The Global Top 5 and Top 10 Largest Drugs of UDCA and t-UDCA Players Market Share by Revenue
  2.7.3 Global Drugs of UDCA and t-UDCA Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans

3 DRUGS OF UDCA AND T-UDCA RETROSPECTIVE MARKET SCENARIO BY REGION

3.1 Global Drugs of UDCA and t-UDCA Market Size by Region: 2018 Versus 2022 Versus 2029
3.2 Global Drugs of UDCA and t-UDCA Global Drugs of UDCA and t-UDCA Sales by Region: 2018-2029
  3.2.1 Global Drugs of UDCA and t-UDCA Sales by Region: 2018-2023
  3.2.2 Global Drugs of UDCA and t-UDCA Sales by Region: 2024-2029
3.3 Global Drugs of UDCA and t-UDCA Global Drugs of UDCA and t-UDCA Revenue by Region: 2018-2029
  3.3.1 Global Drugs of UDCA and t-UDCA Revenue by Region: 2018-2023
  3.3.2 Global Drugs of UDCA and t-UDCA Revenue by Region: 2024-2029
3.4 North America Drugs of UDCA and t-UDCA Market Facts & Figures by Country
  3.4.1 North America Drugs of UDCA and t-UDCA Market Size by Country: 2018 VS 2022 VS 2029
  3.4.2 North America Drugs of UDCA and t-UDCA Sales by Country (2018-2029)
  3.4.3 North America Drugs of UDCA and t-UDCA Revenue by Country (2018-2029)
  3.4.4 United States
  3.4.5 Canada
3.5 Europe Drugs of UDCA and t-UDCA Market Facts & Figures by Country
  3.5.1 Europe Drugs of UDCA and t-UDCA Market Size by Country: 2018 VS 2022 VS 2029
  3.5.2 Europe Drugs of UDCA and t-UDCA Sales by Country (2018-2029)
  3.5.3 Europe Drugs of UDCA and t-UDCA Revenue by Country (2018-2029)
  3.5.4 Germany
  3.5.5 France
  3.5.6 U.K.
  3.5.7 Italy
  3.5.8 Russia
3.6 Asia Pacific Drugs of UDCA and t-UDCA Market Facts & Figures by Country
  3.6.1 Asia Pacific Drugs of UDCA and t-UDCA Market Size by Country: 2018 VS 2022 VS 2029
  3.6.2 Asia Pacific Drugs of UDCA and t-UDCA Sales by Country (2018-2029)
  3.6.3 Asia Pacific Drugs of UDCA and t-UDCA Revenue by Country (2018-2029)
  3.6.4 China
  3.6.5 Japan
  3.6.6 South Korea
  3.6.7 India
  3.6.8 Australia
  3.6.9 China Taiwan
  3.6.10 Indonesia
  3.6.11 Thailand
  3.6.12 Malaysia
3.7 Latin America Drugs of UDCA and t-UDCA Market Facts & Figures by Country
  3.7.1 Latin America Drugs of UDCA and t-UDCA Market Size by Country: 2018 VS 2022 VS 2029
  3.7.2 Latin America Drugs of UDCA and t-UDCA Sales by Country (2018-2029)
  3.7.3 Latin America Drugs of UDCA and t-UDCA Revenue by Country (2018-2029)
  3.7.4 Mexico
  3.7.5 Brazil
  3.7.6 Argentina
3.8 Middle East and Africa Drugs of UDCA and t-UDCA Market Facts & Figures by Country
  3.8.1 Middle East and Africa Drugs of UDCA and t-UDCA Market Size by Country: 2018 VS 2022 VS 2029
  3.8.2 Middle East and Africa Drugs of UDCA and t-UDCA Sales by Country (2018-2029)
  3.8.3 Middle East and Africa Drugs of UDCA and t-UDCA Revenue by Country (2018-2029)
  3.8.4 Turkey
  3.8.5 Saudi Arabia
  3.8.6 UAE

4 SEGMENT BY TYPE

4.1 Global Drugs of UDCA and t-UDCA Sales by Type (2018-2029)
  4.1.1 Global Drugs of UDCA and t-UDCA Sales by Type (2018-2023)
  4.1.2 Global Drugs of UDCA and t-UDCA Sales by Type (2024-2029)
  4.1.3 Global Drugs of UDCA and t-UDCA Sales Market Share by Type (2018-2029)
4.2 Global Drugs of UDCA and t-UDCA Revenue by Type (2018-2029)
  4.2.1 Global Drugs of UDCA and t-UDCA Revenue by Type (2018-2023)
  4.2.2 Global Drugs of UDCA and t-UDCA Revenue by Type (2024-2029)
  4.2.3 Global Drugs of UDCA and t-UDCA Revenue Market Share by Type (2018-2029)
4.3 Global Drugs of UDCA and t-UDCA Price by Type (2018-2029)

5 SEGMENT BY APPLICATION

5.1 Global Drugs of UDCA and t-UDCA Sales by Application (2018-2029)
  5.1.1 Global Drugs of UDCA and t-UDCA Sales by Application (2018-2023)
  5.1.2 Global Drugs of UDCA and t-UDCA Sales by Application (2024-2029)
  5.1.3 Global Drugs of UDCA and t-UDCA Sales Market Share by Application (2018-2029)
5.2 Global Drugs of UDCA and t-UDCA Revenue by Application (2018-2029)
  5.2.1 Global Drugs of UDCA and t-UDCA Revenue by Application (2018-2023)
  5.2.2 Global Drugs of UDCA and t-UDCA Revenue by Application (2024-2029)
  5.2.3 Global Drugs of UDCA and t-UDCA Revenue Market Share by Application (2018-2029)
5.3 Global Drugs of UDCA and t-UDCA Price by Application (2018-2029)

6 KEY COMPANIES PROFILED

6.1 Dr. Falk Pharma
  6.1.1 Dr. Falk Pharma Corporation Information
  6.1.2 Dr. Falk Pharma Description and Business Overview
  6.1.3 Dr. Falk Pharma Drugs of UDCA and t-UDCA Sales, Revenue and Gross Margin (2018-2023)
  6.1.4 Dr. Falk Pharma Drugs of UDCA and t-UDCA Product Portfolio
  6.1.5 Dr. Falk Pharma Recent Developments/Updates
6.2 Daewoong Pharmaceutical
  6.2.1 Daewoong Pharmaceutical Corporation Information
  6.2.2 Daewoong Pharmaceutical Description and Business Overview
  6.2.3 Daewoong Pharmaceutical Drugs of UDCA and t-UDCA Sales, Revenue and Gross Margin (2018-2023)
  6.2.4 Daewoong Pharmaceutical Drugs of UDCA and t-UDCA Product Portfolio
  6.2.5 Daewoong Pharmaceutical Recent Developments/Updates
6.3 Teva
  6.3.1 Teva Corporation Information
  6.3.2 Teva Description and Business Overview
  6.3.3 Teva Drugs of UDCA and t-UDCA Sales, Revenue and Gross Margin (2018-2023)
  6.3.4 Teva Drugs of UDCA and t-UDCA Product Portfolio
  6.3.5 Teva Recent Developments/Updates
6.4 Epic Pharma
  6.4.1 Epic Pharma Corporation Information
  6.4.2 Epic Pharma Description and Business Overview
  6.4.3 Epic Pharma Drugs of UDCA and t-UDCA Sales, Revenue and Gross Margin (2018-2023)
  6.4.4 Epic Pharma Drugs of UDCA and t-UDCA Product Portfolio
  6.4.5 Epic Pharma Recent Developments/Updates
6.5 Mitsubishi Tanabe Pharma
  6.5.1 Mitsubishi Tanabe Pharma Corporation Information
  6.5.2 Mitsubishi Tanabe Pharma Description and Business Overview
  6.5.3 Mitsubishi Tanabe Pharma Drugs of UDCA and t-UDCA Sales, Revenue and Gross Margin (2018-2023)
  6.5.4 Mitsubishi Tanabe Pharma Drugs of UDCA and t-UDCA Product Portfolio
  6.5.5 Mitsubishi Tanabe Pharma Recent Developments/Updates
6.6 Lannett
  6.6.1 Lannett Corporation Information
  6.6.2 Lannett Description and Business Overview
  6.6.3 Lannett Drugs of UDCA and t-UDCA Sales, Revenue and Gross Margin (2018-2023)
  6.6.4 Lannett Drugs of UDCA and t-UDCA Product Portfolio
  6.6.5 Lannett Recent Developments/Updates
6.7 Viatris
  6.6.1 Viatris Corporation Information
  6.6.2 Viatris Description and Business Overview
  6.6.3 Viatris Drugs of UDCA and t-UDCA Sales, Revenue and Gross Margin (2018-2023)
  6.4.4 Viatris Drugs of UDCA and t-UDCA Product Portfolio
  6.7.5 Viatris Recent Developments/Updates
6.8 Bruschettini
  6.8.1 Bruschettini Corporation Information
  6.8.2 Bruschettini Description and Business Overview
  6.8.3 Bruschettini Drugs of UDCA and t-UDCA Sales, Revenue and Gross Margin (2018-2023)
  6.8.4 Bruschettini Drugs of UDCA and t-UDCA Product Portfolio
  6.8.5 Bruschettini Recent Developments/Updates
6.9 Impax
  6.9.1 Impax Corporation Information
  6.9.2 Impax Description and Business Overview
  6.9.3 Impax Drugs of UDCA and t-UDCA Sales, Revenue and Gross Margin (2018-2023)
  6.9.4 Impax Drugs of UDCA and t-UDCA Product Portfolio
  6.9.5 Impax Recent Developments/Updates
6.10 Shanghai Pharma
  6.10.1 Shanghai Pharma Corporation Information
  6.10.2 Shanghai Pharma Description and Business Overview
  6.10.3 Shanghai Pharma Drugs of UDCA and t-UDCA Sales, Revenue and Gross Margin (2018-2023)
  6.10.4 Shanghai Pharma Drugs of UDCA and t-UDCA Product Portfolio
  6.10.5 Shanghai Pharma Recent Developments/Updates
6.11 Grindeks
  6.11.1 Grindeks Corporation Information
  6.11.2 Grindeks Drugs of UDCA and t-UDCA Description and Business Overview
  6.11.3 Grindeks Drugs of UDCA and t-UDCA Sales, Revenue and Gross Margin (2018-2023)
  6.11.4 Grindeks Drugs of UDCA and t-UDCA Product Portfolio
  6.11.5 Grindeks Recent Developments/Updates

7 INDUSTRY CHAIN AND SALES CHANNELS ANALYSIS

7.1 Drugs of UDCA and t-UDCA Industry Chain Analysis
7.2 Drugs of UDCA and t-UDCA Key Raw Materials
  7.2.1 Key Raw Materials
  7.2.2 Raw Materials Key Suppliers
7.3 Drugs of UDCA and t-UDCA Production Mode & Process
7.4 Drugs of UDCA and t-UDCA Sales and Marketing
  7.4.1 Drugs of UDCA and t-UDCA Sales Channels
  7.4.2 Drugs of UDCA and t-UDCA Distributors
7.5 Drugs of UDCA and t-UDCA Customers

8 DRUGS OF UDCA AND T-UDCA MARKET DYNAMICS

8.1 Drugs of UDCA and t-UDCA Industry Trends
8.2 Drugs of UDCA and t-UDCA Market Drivers
8.3 Drugs of UDCA and t-UDCA Market Challenges
8.4 Drugs of UDCA and t-UDCA Market Restraints

9 RESEARCH FINDING AND CONCLUSION


10 METHODOLOGY AND DATA SOURCE

10.1 Methodology/Research Approach
  10.1.1 Research Programs/Design
  10.1.2 Market Size Estimation
  10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
  10.2.1 Secondary Sources
  10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer

LIST OF TABLES

Table 1. Global Drugs of UDCA and t-UDCA Market Value Comparison by Type (2023-2029) & (US$ Million)
Table 2. Global Drugs of UDCA and t-UDCA Market Value Comparison by Application (2023-2029) & (US$ Million)
Table 3. Global Drugs of UDCA and t-UDCA Market Competitive Situation by Manufacturers in 2022
Table 4. Global Drugs of UDCA and t-UDCA Sales (K Units) of Key Manufacturers (2018-2023)
Table 5. Global Drugs of UDCA and t-UDCA Sales Market Share by Manufacturers (2018-2023)
Table 6. Global Drugs of UDCA and t-UDCA Revenue (US$ Million) by Manufacturers (2018-2023)
Table 7. Global Drugs of UDCA and t-UDCA Revenue Share by Manufacturers (2018-2023)
Table 8. Global Market Drugs of UDCA and t-UDCA Average Price (US$/Unit) of Key Manufacturers (2018-2023)
Table 9. Global Key Players of Drugs of UDCA and t-UDCA, Industry Ranking, 2021 VS 2022 VS 2023
Table 10. Global Key Manufacturers of Drugs of UDCA and t-UDCA, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Drugs of UDCA and t-UDCA, Product Type & Application
Table 12. Global Key Manufacturers of Drugs of UDCA and t-UDCA, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Drugs of UDCA and t-UDCA by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Drugs of UDCA and t-UDCA as of 2022)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Drugs of UDCA and t-UDCA Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
Table 17. Global Drugs of UDCA and t-UDCA Sales by Region (2018-2023) & (K Units)
Table 18. Global Drugs of UDCA and t-UDCA Sales Market Share by Region (2018-2023)
Table 19. Global Drugs of UDCA and t-UDCA Sales by Region (2024-2029) & (K Units)
Table 20. Global Drugs of UDCA and t-UDCA Sales Market Share by Region (2024-2029)
Table 21. Global Drugs of UDCA and t-UDCA Revenue by Region (2018-2023) & (US$ Million)
Table 22. Global Drugs of UDCA and t-UDCA Revenue Market Share by Region (2018-2023)
Table 23. Global Drugs of UDCA and t-UDCA Revenue by Region (2024-2029) & (US$ Million)
Table 24. Global Drugs of UDCA and t-UDCA Revenue Market Share by Region (2024-2029)
Table 25. North America Drugs of UDCA and t-UDCA Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 26. North America Drugs of UDCA and t-UDCA Sales by Country (2018-2023) & (K Units)
Table 27. North America Drugs of UDCA and t-UDCA Sales by Country (2024-2029) & (K Units)
Table 28. North America Drugs of UDCA and t-UDCA Revenue by Country (2018-2023) & (US$ Million)
Table 29. North America Drugs of UDCA and t-UDCA Revenue by Country (2024-2029) & (US$ Million)
Table 30. Europe Drugs of UDCA and t-UDCA Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 31. Europe Drugs of UDCA and t-UDCA Sales by Country (2018-2023) & (K Units)
Table 32. Europe Drugs of UDCA and t-UDCA Sales by Country (2024-2029) & (K Units)
Table 33. Europe Drugs of UDCA and t-UDCA Revenue by Country (2018-2023) & (US$ Million)
Table 34. Europe Drugs of UDCA and t-UDCA Revenue by Country (2024-2029) & (US$ Million)
Table 35. Asia Pacific Drugs of UDCA and t-UDCA Revenue by Region: 2018 VS 2022 VS 2029 (US$ Million)
Table 36. Asia Pacific Drugs of UDCA and t-UDCA Sales by Region (2018-2023) & (K Units)
Table 37. Asia Pacific Drugs of UDCA and t-UDCA Sales by Region (2024-2029) & (K Units)
Table 38. Asia Pacific Drugs of UDCA and t-UDCA Revenue by Region (2018-2023) & (US$ Million)
Table 39. Asia Pacific Drugs of UDCA and t-UDCA Revenue by Region (2024-2029) & (US$ Million)
Table 40. Latin America Drugs of UDCA and t-UDCA Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 41. Latin America Drugs of UDCA and t-UDCA Sales by Country (2018-2023) & (K Units)
Table 42. Latin America Drugs of UDCA and t-UDCA Sales by Country (2024-2029) & (K Units)
Table 43. Latin America Drugs of UDCA and t-UDCA Revenue by Country (2018-2023) & (US$ Million)
Table 44. Latin America Drugs of UDCA and t-UDCA Revenue by Country (2024-2029) & (US$ Million)
Table 45. Middle East & Africa Drugs of UDCA and t-UDCA Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 46. Middle East & Africa Drugs of UDCA and t-UDCA Sales by Country (2018-2023) & (K Units)
Table 47. Middle East & Africa Drugs of UDCA and t-UDCA Sales by Country (2024-2029) & (K Units)
Table 48. Middle East & Africa Drugs of UDCA and t-UDCA Revenue by Country (2018-2023) & (US$ Million)
Table 49. Middle East & Africa Drugs of UDCA and t-UDCA Revenue by Country (2024-2029) & (US$ Million)
Table 50. Global Drugs of UDCA and t-UDCA Sales (K Units) by Type (2018-2023)
Table 51. Global Drugs of UDCA and t-UDCA Sales (K Units) by Type (2024-2029)
Table 52. Global Drugs of UDCA and t-UDCA Sales Market Share by Type (2018-2023)
Table 53. Global Drugs of UDCA and t-UDCA Sales Market Share by Type (2024-2029)
Table 54. Global Drugs of UDCA and t-UDCA Revenue (US$ Million) by Type (2018-2023)
Table 55. Global Drugs of UDCA and t-UDCA Revenue (US$ Million) by Type (2024-2029)
Table 56. Global Drugs of UDCA and t-UDCA Revenue Market Share by Type (2018-2023)
Table 57. Global Drugs of UDCA and t-UDCA Revenue Market Share by Type (2024-2029)
Table 58. Global Drugs of UDCA and t-UDCA Price (US$/Unit) by Type (2018-2023)
Table 59. Global Drugs of UDCA and t-UDCA Price (US$/Unit) by Type (2024-2029)
Table 60. Global Drugs of UDCA and t-UDCA Sales (K Units) by Application (2018-2023)
Table 61. Global Drugs of UDCA and t-UDCA Sales (K Units) by Application (2024-2029)
Table 62. Global Drugs of UDCA and t-UDCA Sales Market Share by Application (2018-2023)
Table 63. Global Drugs of UDCA and t-UDCA Sales Market Share by Application (2024-2029)
Table 64. Global Drugs of UDCA and t-UDCA Revenue (US$ Million) by Application (2018-2023)
Table 65. Global Drugs of UDCA and t-UDCA Revenue (US$ Million) by Application (2024-2029)
Table 66. Global Drugs of UDCA and t-UDCA Revenue Market Share by Application (2018-2023)
Table 67. Global Drugs of UDCA and t-UDCA Revenue Market Share by Application (2024-2029)
Table 68. Global Drugs of UDCA and t-UDCA Price (US$/Unit) by Application (2018-2023)
Table 69. Global Drugs of UDCA and t-UDCA Price (US$/Unit) by Application (2024-2029)
Table 70. Dr. Falk Pharma Corporation Information
Table 71. Dr. Falk Pharma Description and Business Overview
Table 72. Dr. Falk Pharma Drugs of UDCA and t-UDCA Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 73. Dr. Falk Pharma Drugs of UDCA and t-UDCA Product
Table 74. Dr. Falk Pharma Recent Developments/Updates
Table 75. Daewoong Pharmaceutical Corporation Information
Table 76. Daewoong Pharmaceutical Description and Business Overview
Table 77. Daewoong Pharmaceutical Drugs of UDCA and t-UDCA Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 78. Daewoong Pharmaceutical Drugs of UDCA and t-UDCA Product
Table 79. Daewoong Pharmaceutical Recent Developments/Updates
Table 80. Teva Corporation Information
Table 81. Teva Description and Business Overview
Table 82. Teva Drugs of UDCA and t-UDCA Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 83. Teva Drugs of UDCA and t-UDCA Product
Table 84. Teva Recent Developments/Updates
Table 85. Epic Pharma Corporation Information
Table 86. Epic Pharma Description and Business Overview
Table 87. Epic Pharma Drugs of UDCA and t-UDCA Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 88. Epic Pharma Drugs of UDCA and t-UDCA Product
Table 89. Epic Pharma Recent Developments/Updates
Table 90. Mitsubishi Tanabe Pharma Corporation Information
Table 91. Mitsubishi Tanabe Pharma Description and Business Overview
Table 92. Mitsubishi Tanabe Pharma Drugs of UDCA and t-UDCA Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 93. Mitsubishi Tanabe Pharma Drugs of UDCA and t-UDCA Product
Table 94. Mitsubishi Tanabe Pharma Recent Developments/Updates
Table 95. Lannett Corporation Information
Table 96. Lannett Description and Business Overview
Table 97. Lannett Drugs of UDCA and t-UDCA Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 98. Lannett Drugs of UDCA and t-UDCA Product
Table 99. Lannett Recent Developments/Updates
Table 100. Viatris Corporation Information
Table 101. Viatris Description and Business Overview
Table 102. Viatris Drugs of UDCA and t-UDCA Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 103. Viatris Drugs of UDCA and t-UDCA Product
Table 104. Viatris Recent Developments/Updates
Table 105. Bruschettini Corporation Information
Table 106. Bruschettini Description and Business Overview
Table 107. Bruschettini Drugs of UDCA and t-UDCA Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 108. Bruschettini Drugs of UDCA and t-UDCA Product
Table 109. Bruschettini Recent Developments/Updates
Table 110. Impax Corporation Information
Table 111. Impax Description and Business Overview
Table 112. Impax Drugs of UDCA and t-UDCA Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 113. Impax Drugs of UDCA and t-UDCA Product
Table 114. Impax Recent Developments/Updates
Table 115. Shanghai Pharma Corporation Information
Table 116. Shanghai Pharma Description and Business Overview
Table 117. Shanghai Pharma Drugs of UDCA and t-UDCA Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 118. Shanghai Pharma Drugs of UDCA and t-UDCA Product
Table 119. Shanghai Pharma Recent Developments/Updates
Table 120. Grindeks Corporation Information
Table 121. Grindeks Description and Business Overview
Table 122. Grindeks Drugs of UDCA and t-UDCA Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 123. Grindeks Drugs of UDCA and t-UDCA Product
Table 124. Grindeks Recent Developments/Updates
Table 125. Key Raw Materials Lists
Table 126. Raw Materials Key Suppliers Lists
Table 127. Drugs of UDCA and t-UDCA Distributors List
Table 128. Drugs of UDCA and t-UDCA Customers List
Table 129. Drugs of UDCA and t-UDCA Market Trends
Table 130. Drugs of UDCA and t-UDCA Market Drivers
Table 131. Drugs of UDCA and t-UDCA Market Challenges
Table 132. Drugs of UDCA and t-UDCA Market Restraints
Table 133. Research Programs/Design for This Report
Table 134. Key Data Information from Secondary Sources
Table 135. Key Data Information from Primary Sources

LIST OF FIGURES

Figure 1. Product Picture of Drugs of UDCA and t-UDCA
Figure 2. Global Drugs of UDCA and t-UDCA Market Value Comparison by Type (2023-2029) & (US$ Million)
Figure 3. Global Drugs of UDCA and t-UDCA Market Share by Type in 2022 & 2029
Figure 4. t-UDCA Product Picture
Figure 5. UDCA Product Picture
Figure 6. Global Drugs of UDCA and t-UDCA Market Value Comparison by Application (2023-2029) & (US$ Million)
Figure 7. Global Drugs of UDCA and t-UDCA Market Share by Application in 2022 & 2029
Figure 8. Gallstone
Figure 9. Hepatopathy
Figure 10. Biliary Disease
Figure 11. Other
Figure 12. Global Drugs of UDCA and t-UDCA Revenue, (US$ Million), 2018 VS 2022 VS 2029
Figure 13. Global Drugs of UDCA and t-UDCA Market Size (2018-2029) & (US$ Million)
Figure 14. Global Drugs of UDCA and t-UDCA Sales (2018-2029) & (K Units)
Figure 15. Global Drugs of UDCA and t-UDCA Average Price (US$/Unit) & (2018-2029)
Figure 16. Drugs of UDCA and t-UDCA Report Years Considered
Figure 17. Drugs of UDCA and t-UDCA Sales Share by Manufacturers in 2022
Figure 18. Global Drugs of UDCA and t-UDCA Revenue Share by Manufacturers in 2022
Figure 19. The Global 5 and 10 Largest Drugs of UDCA and t-UDCA Players: Market Share by Revenue in 2022
Figure 20. Drugs of UDCA and t-UDCA Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2018 VS 2022
Figure 21. Global Drugs of UDCA and t-UDCA Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
Figure 22. North America Drugs of UDCA and t-UDCA Sales Market Share by Country (2018-2029)
Figure 23. North America Drugs of UDCA and t-UDCA Revenue Market Share by Country (2018-2029)
Figure 24. United States Drugs of UDCA and t-UDCA Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 25. Canada Drugs of UDCA and t-UDCA Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 26. Europe Drugs of UDCA and t-UDCA Sales Market Share by Country (2018-2029)
Figure 27. Europe Drugs of UDCA and t-UDCA Revenue Market Share by Country (2018-2029)
Figure 28. Germany Drugs of UDCA and t-UDCA Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 29. France Drugs of UDCA and t-UDCA Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 30. U.K. Drugs of UDCA and t-UDCA Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 31. Italy Drugs of UDCA and t-UDCA Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 32. Russia Drugs of UDCA and t-UDCA Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 33. Asia Pacific Drugs of UDCA and t-UDCA Sales Market Share by Region (2018-2029)
Figure 34. Asia Pacific Drugs of UDCA and t-UDCA Revenue Market Share by Region (2018-2029)
Figure 35. China Drugs of UDCA and t-UDCA Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 36. Japan Drugs of UDCA and t-UDCA Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 37. South Korea Drugs of UDCA and t-UDCA Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 38. India Drugs of UDCA and t-UDCA Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 39. Australia Drugs of UDCA and t-UDCA Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 40. China Taiwan Drugs of UDCA and t-UDCA Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 41. Indonesia Drugs of UDCA and t-UDCA Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 42. Thailand Drugs of UDCA and t-UDCA Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 43. Malaysia Drugs of UDCA and t-UDCA Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 44. Latin America Drugs of UDCA and t-UDCA Sales Market Share by Country (2018-2029)
Figure 45. Latin America Drugs of UDCA and t-UDCA Revenue Market Share by Country (2018-2029)
Figure 46. Mexico Drugs of UDCA and t-UDCA Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 47. Brazil Drugs of UDCA and t-UDCA Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 48. Argentina Drugs of UDCA and t-UDCA Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 49. Middle East & Africa Drugs of UDCA and t-UDCA Sales Market Share by Country (2018-2029)
Figure 50. Middle East & Africa Drugs of UDCA and t-UDCA Revenue Market Share by Country (2018-2029)
Figure 51. Turkey Drugs of UDCA and t-UDCA Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 52. Saudi Arabia Drugs of UDCA and t-UDCA Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 53. UAE Drugs of UDCA and t-UDCA Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 54. Global Sales Market Share of Drugs of UDCA and t-UDCA by Type (2018-2029)
Figure 55. Global Revenue Market Share of Drugs of UDCA and t-UDCA by Type (2018-2029)
Figure 56. Global Drugs of UDCA and t-UDCA Price (US$/Unit) by Type (2018-2029)
Figure 57. Global Sales Market Share of Drugs of UDCA and t-UDCA by Application (2018-2029)
Figure 58. Global Revenue Market Share of Drugs of UDCA and t-UDCA by Application (2018-2029)
Figure 59. Global Drugs of UDCA and t-UDCA Price (US$/Unit) by Application (2018-2029)
Figure 60. Drugs of UDCA and t-UDCA Value Chain
Figure 61. Drugs of UDCA and t-UDCA Production Process
Figure 62. Channels of Distribution (Direct Vs Distribution)
Figure 63. Distributors Profiles
Figure 64. Bottom-up and Top-down Approaches for This Report
Figure 65. Data Triangulation
Figure 66. Key Executives Interviewed


More Publications